Ratings by Oppenheimer (Trevor Allred)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/31/2026 | Palvella Therapeutics | PVLA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/9/2026 | Dianthus Therapeutics | DNTH | Maintain | Outperform (N/A) |
|
Details | ||
| 3/5/2026 | Theravance Biopharma | TBPH | Downgrade | Perform (Outperform) |
13.67 (16.97) |
24.14% | Details | |
| 2/27/2026 | Ligand Pharma | LGND | Maintain | Outperform (N/A) |
|
Details | ||
| 1/29/2026 | Dianthus Therapeutics | DNTH | Maintain | Outperform (N/A) |
|
Details | ||
| 1/7/2026 | Legend Biotech Corp. | LEGN | New Coverage | Outperform (N/A) |
20.98 (29.30) |
39.66% | Details | |
| 12/15/2025 | Palvella Therapeutics | PVLA | Maintain | Outperform (N/A) |
|
Details | ||
| 12/10/2025 | Ligand Pharma | LGND | Maintain | Outperform (Outperform) |
|
Details | ||
| 12/3/2025 | Theravance Biopharma | TBPH | New Coverage | Outperform (N/A) |
18.43 (13.67) |
-25.83% | Details | |
| 11/11/2025 | Palvella Therapeutics | PVLA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/7/2025 | Ligand Pharma | LGND | Maintain | Outperform (N/A) |
|
Details | ||
| 11/6/2025 | Dianthus Therapeutics | DNTH | Maintain | Outperform (N/A) |
|
Details | ||
| 11/3/2025 | Ligand Pharma | LGND | Maintain | Outperform (N/A) |
|
Details | ||
| 10/16/2025 | Dianthus Therapeutics | DNTH | Maintain | Outperform (N/A) |
|
Details | ||
| 10/15/2025 | MBX Biosciences Inc | MBX | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/24/2025 | Palvella Therapeutics | PVLA | Maintain | Outperform (N/A) |
|
Details | ||
| 9/23/2025 | MBX Biosciences Inc | MBX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/9/2025 | Palvella Therapeutics | PVLA | New Coverage | Outperform (N/A) |
55.02 (126.84) |
130.53% | Details | |
| 9/3/2025 | Ligand Pharma | LGND | Maintain | Outperform (N/A) |
|
Details | ||
| 8/11/2025 | Inova Technology, Inc. | INVA | New Coverage | Outperform (N/A) |
18.34 (23.55) |
28.41% | Details | |
| 8/7/2025 | Ligand Pharma | LGND | Maintain | Outperform (N/A) |
|
Details | ||
| 7/30/2025 | Ligand Pharma | LGND | Maintain | Outperform (N/A) |
|
Details | ||
| 7/23/2025 | MBX Biosciences Inc | MBX | Maintain | Outperform (Outperform) |
|
Details | ||
| 7/16/2025 | MBX Biosciences Inc | MBX | New Coverage | Outperform (N/A) |
13.40 (29.78) |
122.24% | Details | |
| 5/9/2025 | Ligand Pharma | LGND | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2025 | Ligand Pharma | LGND | Maintain | Outperform (N/A) |
|
Details | ||
| 12/11/2024 | Ligand Pharma | LGND | Maintain | Outperform (N/A) |
|
Details |
